Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The Immunodeficiency Foundation’s archival mission has long centered on the broad dissemination of general health and science information, with a particular emphasis on the historical and scientific records that illuminate complex medical conditions. This legacy of providing accessible, neutral reference material has served as a foundational resource for understanding the interplay between therapeutic interventions and patient outcomes. Within this context, the Foundation’s curated archives have increasingly documented the evolution of pharmacovigilance, including the identification of rare adverse events associated with widely prescribed medications. One such area of growing interest involves the relationship between bisphosphonate therapy, specifically Fosamax, and the development of osteonecrosis of the jaw. This condition, characterized by exposed necrotic bone in the maxillofacial region, has prompted extensive scientific inquiry into its causation.

Bridging to Clinical and Occupational Concerns

The transition from general health education to a more focused examination of occupational exposure risk emerges naturally from this archival work. As the Foundation continues to catalog the scientific evidence connecting Fosamax to osteonecrosis of the jaw, it becomes imperative to consider the implications for healthcare professionals who may encounter these patients in clinical settings. This pivot from broad health literacy to specific occupational concern underscores the Foundation’s commitment to bridging historical knowledge with contemporary practice, ensuring that archived insights inform current risk assessment and patient management strategies.

Fosamax and Osteonecrosis of the Jaw: Scientific Evidence

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence. However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves delayed healing after dental procedures, such as tooth extraction or dental implant placement, often accompanied by local infection. The condition can also occur spontaneously. Diagnosis is based on clinical examination and imaging, with the hallmark being persistent bone exposure for more than eight weeks in the absence of radiation therapy to the jaws. The scientific evidence establishes a clear link between Fosamax use and ONJ, as documented in FDA-approved labeling. The labeling for Fosamax explicitly states: "Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning is also present in the labeling for Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling further identifies known risk factors for ONJ, including invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistic pathways linking Fosamax to ONJ are supported by preclinical research. A multiscale characterization study of jawbone in estrogen-deficient rats treated with bisphosphonate (alendronate) found that bisphosphonate treatment affects jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research provides comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The proposed mechanism involves bisphosphonate accumulation in the jawbone, suppression of bone turnover, and impaired healing of microdamage, particularly in areas of high mechanical stress or after dental trauma.

Risk Considerations and Clinical Implications

Regarding risk considerations, the adequacy of warnings in Fosamax labeling is a critical issue. The labeling includes a dedicated section on ONJ, describing its association with bisphosphonate use and listing risk factors. However, the labeling also notes that in placebo-controlled clinical studies, the percentages of patients with certain symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This may create ambiguity about the strength of the causal link, though the overall evidence supports a causal association. For affected patients, causation-related considerations are important. The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between Fosamax exposure and documented harm is variable. ONJ can develop within days to months after starting the drug, but it is often associated with dental procedures that occur during treatment. The labeling advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This underscores the importance of risk-benefit assessment in long-term therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

The scientific evidence establishes a clear link between Fosamax use and ONJ, as documented in FDA-approved labeling. The labeling for Fosamax explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Mechanistic studies, such as a multiscale characterization of jawbone in rats, show that bisphosphonate treatment affects jawbone properties, providing insight into the pathophysiology (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can osteonecrosis of the jaw develop?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It is often associated with dental procedures that occur during treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.